Please assess the completion status of the following clinical trial:

Trial Title: DAS181 for Severe COVID-19: Compassionate Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens~2. Hypoxemic~3. Severe COVID-19~4. If female, subject must not be pregnant or nursing.~5. Non-vasectomized males are required to practice effective birth control methods~6. Capable of understanding and complying with procedures as outlined in the protocol as judged by the Investigator and able to sign informed consent form prior to the initiation of any screening or study-specific procedures.~Exclusion Criteria:~1. ALT or AST\> 8 x ULN~2. (ALT or AST\> 3 x ULN) and (Total bilirubin\> 2.5 x ULN or INR\> 2.0 x ULN)~3. Female subjects who have a positive pregnancy test and are breastfeeding~4. Subjects using any other investigational antiviral drugs during the hospitalization before enrollment.~5. Subjects participating in other clinical trials~6. Subjects may be transferred to a non-participating hospital within 72 hours~7. People who cannot cooperate well due to mental illness, have no self-control, and cannot express clearly~8. Severe underlying diseases affecting survival~9. Critical COVID-19 requiring mechanical ventilator at the time enrolled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DAS181 Treatment (Type: EXPERIMENTAL): Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).